Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Krystal Biotech, Inc. (KRYS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$300.25-3.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
9.35 → 9.27 EPS · FY ending Dec 31, 2027 · 8 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 8; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for KRYS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Net income rises above $55 million | Profit and net income are rising, with operating income up $12 million since 2025. | Intact | Net income falls below $51 million | Net income: $63.068M FY2026-Q3; GAAP. Published target: >= $55.9 million. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Nov 2, 202663,068,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a commercial-growth and pipeline business, with the multi-year view centered on expanding VYJUVEK and advancing clinical programs. The thesis is intact, and recent financial performance is strong, but confidence is medium and earnings quality is neutral.
KRYS is expensive versus peers, with a durable premium and a negative expectations gap, meaning expectations appear ahead of what the evidence supports. The model has low confidence, though no fragility gates fired and the premium is tagged as justified.
Near term, VYJUVEK revenue has grown, and management’s global commercialization priority is on track, though the Spain and Italy launches were still planned in the latest disclosure. Pipeline milestones are progressing, but readouts remain pending; expense guidance is unchanged while reported R&D and SG&A costs have risen. Guidance cuts are a key near-term risk, while recent earnings beats and stronger sector context support the setup.
The multi-year view hinges on continued VYJUVEK expansion, delivery against the full-year expense range, and progress toward clinical milestones. Near term, a guidance cut or further weakening in jobs data would be unfavorable; continued earnings strength and higher guidance from sector peers would support the Healthcare backdrop.
Over the next 1 to 3 years, KRYS has a credible growth thesis with commercial progress and an advancing pipeline, but its expensive valuation leaves limited room for execution to falter. The thesis depends on sustained product growth, disciplined spending, and clinical progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Profit and net income are rising, with operating income up $12 million since 2025. |
| Intact |
| Operating income falls below $41 million |
Operating income: $71.145M FY2026-Q3; GAAP. Published target: >= $53.7 million. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Nov 2, 202671,145,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to about $525 million in 2026 | Krystal Biotech grows revenue about 39% yearly, reaching $525 million in 2026. | Improving | Annual revenue falls below $388 million in 2026 | Revenue: $127.341M FY2026-Q3; GAAP. Published target: ~$525 million. Annual target cannot be compared with a quarterly or TTM observation. Nov 2, 2026127,341,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$9.87 → $9.27 · observed estimates
$0.67B → $0.65B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-07-25 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-07-26 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-07-27 | $9.49 | $653,679,038 | 7 / 6 |
| 2026-07-28 | $9.49 | $653,679,038 | 7 / 6 |
| 2026-07-29 | $9.49 | $653,679,038 | 7 / 6 |
| 2026-07-30 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-07-31 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-08-01 | $9.49 | $653,679,038 | 7 / 6 |
| 2026-08-02 | $9.49 | $653,679,038 | 7 / 6 |
| 2026-08-03 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-08-04 | $9.87 | $670,249,520 | 9 / 8 |
| 2026-08-05 | $9.53 | $654,741,920 | 10 / 8 |
| 2026-08-06 | $9.51 | $646,896,338 | 7 / 6 |
| 2026-08-07 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-08 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-09 | $9.53 | $654,741,920 | 10 / 8 |
| 2026-08-10 | $9.53 | $654,741,920 | 10 / 8 |
| 2026-08-12 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-13 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-14 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-15 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-16 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-17 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-18 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-19 | $9.05 | $641,252,954 | 8 / 6 |
| 2026-08-20 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-21 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-22 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-23 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-24 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-25 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-26 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-27 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-28 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-29 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-30 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-08-31 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-09-01 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-09-02 | $9.43 | $665,488,404 | 8 / 6 |
| 2026-09-03 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-04 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-05 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-06 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-07 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-08 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-09 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-10 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-11 | $9.47 | $665,488,404 | 8 / 6 |
| 2026-09-12 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-13 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-14 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-15 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-16 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-17 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-18 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-19 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-20 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-21 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-22 | $9.47 | $665,508,404 | 8 / 6 |
| 2026-09-23 | $9.39 | $665,508,404 | 8 / 6 |
| 2026-09-24 | $9.39 | $665,508,404 | 8 / 6 |
| 2026-09-25 | $9.35 | $662,066,640 | 9 / 7 |
| 2026-09-26 | $9.35 | $662,066,640 | 8 / 7 |
| 2026-09-27 | $9.35 | $662,066,640 | 8 / 7 |
| 2026-09-28 | $9.35 | $662,066,640 | 9 / 7 |
| 2026-09-29 | $9.35 | $662,066,640 | 9 / 7 |
| 2026-09-30 | $9.35 | $662,066,640 | 9 / 7 |
| 2026-10-01 | $9.35 | $662,066,640 | 9 / 7 |
| 2026-10-02 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-03 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-04 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-05 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-06 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-07 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-08 | $9.35 | $662,066,631 | 9 / 7 |
| 2026-10-09 | $9.30 | $658,775,722 | 9 / 7 |
| 2026-10-10 | $9.30 | $658,775,722 | 9 / 7 |
| 2026-10-11 | $9.30 | $658,775,722 | 9 / 7 |
| 2026-10-12 | $9.30 | $658,775,722 | 9 / 7 |
| 2026-10-13 | $9.30 | $658,775,722 | 9 / 7 |
| 2026-10-14 | $9.24 | $655,598,413 | 9 / 7 |
| 2026-10-15 | $9.24 | $655,598,413 | 9 / 7 |
| 2026-10-16 | $9.24 | $655,598,413 | 8 / 7 |
| 2026-10-17 | $9.24 | $655,598,413 | 8 / 7 |
| 2026-10-18 | $9.11 | $649,773,256 | 9 / 7 |
| 2026-10-19 | $9.11 | $649,773,256 | 9 / 7 |
| 2026-10-20 | $9.11 | $649,773,256 | 9 / 7 |
| 2026-10-21 | $9.11 | $649,773,256 | 9 / 7 |
| 2026-10-22 | $9.02 | $646,036,893 | 9 / 7 |
| 2026-10-23 | $9.02 | $646,036,893 | 9 / 7 |
| 2026-10-24 | $9.02 | $646,036,893 | 9 / 7 |
| 2026-10-25 | $9.02 | $646,036,893 | 9 / 7 |
| 2026-10-26 | $9.02 | $646,036,893 | 9 / 7 |
| 2026-10-27 | $9.02 | $646,036,893 | 9 / 7 |
| 2026-10-28 | $8.86 | $645,720,582 | 9 / 7 |
| 2026-10-29 | $8.86 | $645,720,582 | 9 / 7 |
| 2026-10-30 | $8.86 | $645,720,582 | 9 / 7 |
| 2026-10-31 | $8.86 | $645,720,582 | 9 / 7 |
| 2026-11-01 | $8.86 | $645,720,582 | 9 / 7 |
| 2026-11-02 | $8.86 | $645,720,582 | 9 / 7 |
| 2026-11-03 | $9.33 | $646,497,248 | 8 / 6 |
| 2026-11-04 | $9.27 | $646,497,248 | 8 / 6 |
| 2026-11-05 | $9.27 | $646,497,248 | 8 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 4 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.